A Message from the President
Dear Colleagues,
Here at SITC, Diversity, Equity and Inclusion (DEI) is a core value of the organization – from membership engagement to research to professional development opportunities. It is our goal to weave the value of diversity into all aspects of the society and our DEI Committee plays a big part in that. The committee aims to improve opportunities for research, education, and professional development that promote diversity, equity, and inclusion within the society and field of cancer immunotherapy. The DEI Committee and the SITC leadership are eager to continue developing exceptional initiatives designed to grow our community of diverse global stakeholders.
One of these initiatives is fast approaching. SITC’s virtual Roundtable on Diversity in Clinical Trial Enrollment is taking place on July 25 from 3-6:10 p.m. ET. My co-organizers – Chelsea C. Pinnix, MD, PhD and Padmanee Sharma, MD, PhD, from The University of Texas MD Anderson Cancer Center and John H. Stewart IV, MD, MBA, FACS from LSU-LCMC Health Cancer Center – and I look forward to the presentations and panels. The goal of the roundtable is to develop recommendations for specific actions each stakeholder in the clinical trial ecosystem can take to positively impact diversity in clinical trial enrollment. I encourage you to read more here and register in advance.
Later this year, during National Hispanic Heritage Month, SITC will host a listening session focusing on the Hispanic and Latin communities. More information is to come, but in the meantime, you can catch up on previous sessions here.
We are pleased to continue this series of DEI panels! Here’s to breaking down barriers and working towards the ultimate goal of eliminating cancer world-wide.
Sincerely,
Leisha A. Emens, MD, PhD
SITC President